Sanofi (ENXTPA:SAN) has drawn fresh attention after positive phase 3 data for amlitelimab in atopic dermatitis and Japanese approval of Dupixent for bullous pemphigoid, both reinforcing its immunology ...

The German retailer said the FDI approval process in Austria remains pending, even as the deal has secured clearances in several other jurisdictions.